Brigatinib: First Global Approval.
Article Details
- CitationCopy to clipboard
Markham A
Brigatinib: First Global Approval.
Drugs. 2017 Jul;77(10):1131-1135. doi: 10.1007/s40265-017-0776-3.
- PubMed ID
- 28597393 [ View in PubMed]
- Abstract
Brigatinib (ALUNBRIG) is a small molecule antineoplastic anaplastic lymphoma kinase (ALK) inhibitor being developed by ARIAD Pharmaceuticals (a wholly-owned subsidiary of Takeda Pharmaceutical Company). In April 2017 brigatinib received accelerated approval in the USA for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. The development of resistance to crizotinib is a therapeutic challenge that has led to the development of second-generation ALK-inhibitors such as brigatinib, which have activity against treatment-resistant ALK mutants. This article summarizes the milestones in the development of brigatinib leading to this first global approval for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib.
DrugBank Data that Cites this Article
- Drugs
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Brigatinib ALK tyrosine kinase receptor Protein Humans YesInhibitorDetails Brigatinib Epidermal growth factor receptor Protein Humans YesInhibitorDetails Brigatinib Insulin-like growth factor 1 receptor Protein Humans UnknownInhibitorDetails Brigatinib Receptor-type tyrosine-protein kinase FLT3 Protein Humans UnknownInhibitorDetails Brigatinib Tyrosine-protein kinase ABL1 Protein Humans UnknownInhibitorDetails - Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Brigatinib Cytochrome P450 2C8 Protein Humans NoSubstrateDetails Brigatinib Cytochrome P450 3A4 Protein Humans NoSubstrateDetails - Drug Reactions
Reaction Details